BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 25127090)

  • 1. Continuous subcutaneous hydrocortisone infusion therapy in Addison's disease: a randomized, placebo-controlled clinical trial.
    Gagliardi L; Nenke MA; Thynne TR; von der Borch J; Rankin WA; Henley DE; Sorbello J; Inder WJ; Torpy DJ
    J Clin Endocrinol Metab; 2014 Nov; 99(11):4149-57. PubMed ID: 25127090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circadian hormone profiles and insulin sensitivity in patients with Addison's disease: a comparison of continuous subcutaneous hydrocortisone infusion with conventional glucocorticoid replacement therapy.
    Björnsdottir S; Øksnes M; Isaksson M; Methlie P; Nilsen RM; Hustad S; Kämpe O; Hulting AL; Husebye ES; Løvås K; Nyström T; Bensing S
    Clin Endocrinol (Oxf); 2015 Jul; 83(1):28-35. PubMed ID: 25400085
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous subcutaneous hydrocortisone infusion versus oral hydrocortisone replacement for treatment of addison's disease: a randomized clinical trial.
    Oksnes M; Björnsdottir S; Isaksson M; Methlie P; Carlsen S; Nilsen RM; Broman JE; Triebner K; Kämpe O; Hulting AL; Bensing S; Husebye ES; Løvås K
    J Clin Endocrinol Metab; 2014 May; 99(5):1665-74. PubMed ID: 24517155
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continuous subcutaneous hydrocortisone infusion in Addison's disease.
    Løvås K; Husebye ES
    Eur J Endocrinol; 2007 Jul; 157(1):109-12. PubMed ID: 17609409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Phase 2 Study of Continuous Subcutaneous Hydrocortisone Infusion in Adults With Congenital Adrenal Hyperplasia.
    Nella AA; Mallappa A; Perritt AF; Gounden V; Kumar P; Sinaii N; Daley LA; Ling A; Liu CY; Soldin SJ; Merke DP
    J Clin Endocrinol Metab; 2016 Dec; 101(12):4690-4698. PubMed ID: 27680873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improvement of anthropometric and metabolic parameters, and quality of life following treatment with dual-release hydrocortisone in patients with Addison's disease.
    Giordano R; Guaraldi F; Marinazzo E; Fumarola F; Rampino A; Berardelli R; Karamouzis I; Lucchiari M; Manetta T; Mengozzi G; Arvat E; Ghigo E
    Endocrine; 2016 Feb; 51(2):360-8. PubMed ID: 26184416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Salivary cortisol day curves in assessing glucocorticoid replacement therapy in Addison's disease.
    Smans L; Lentjes E; Hermus A; Zelissen P
    Hormones (Athens); 2013; 12(1):93-100. PubMed ID: 23624135
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Quality of life in patients with Addison's disease: effects of different cortisol replacement modes.
    Riedel M; Wiese A; Schürmeyer TH; Brabant G
    Exp Clin Endocrinol; 1993; 101(2):106-11. PubMed ID: 8405139
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salivary cortisol day curves in Addison's disease in patients on hydrocortisone replacement.
    Ross IL; Levitt NS; Van der Walt JS; Schatz DA; Johannsson G; Haarburger DH; Pillay TS
    Horm Metab Res; 2013 Jan; 45(1):62-8. PubMed ID: 22893258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pulsatile thyrotropin secretion in patients with Addison's disease during variable glucocorticoid therapy.
    Hangaard J; Andersen M; Grodum E; Koldkjaer O; Hagen C
    J Clin Endocrinol Metab; 1996 Jul; 81(7):2502-7. PubMed ID: 8675567
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Low-dose hydrocortisone replacement improves wellbeing and pain tolerance in chronic pain patients with opioid-induced hypocortisolemic responses. A pilot randomized, placebo-controlled trial.
    Nenke MA; Haylock CL; Rankin W; Inder WJ; Gagliardi L; Eldridge C; Rolan P; Torpy DJ
    Psychoneuroendocrinology; 2015 Jun; 56():157-67. PubMed ID: 25827960
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current and emerging therapies for Addison's disease.
    Napier C; Pearce SH
    Curr Opin Endocrinol Diabetes Obes; 2014 Jun; 21(3):147-53. PubMed ID: 24755997
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Salivary Cortisol and Cortisone do not Appear to be Useful Biomarkers for Monitoring Hydrocortisone Replacement in Addison's Disease.
    Ross IL; Lacerda M; Pillay TS; Blom DJ; Johannsson G; Dave JA; Levitt NS; Haarburger D; van der Walt JS
    Horm Metab Res; 2016 Dec; 48(12):814-821. PubMed ID: 27813051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A randomized, double-blind, crossover study comparing two- and four-dose hydrocortisone regimen with regard to quality of life, cortisol and ACTH profiles in patients with primary adrenal insufficiency.
    Ekman B; Bachrach-Lindström M; Lindström T; Wahlberg J; Blomgren J; Arnqvist HJ
    Clin Endocrinol (Oxf); 2012 Jul; 77(1):18-25. PubMed ID: 22288685
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Circadian hydrocortisone infusions in patients with adrenal insufficiency and congenital adrenal hyperplasia.
    Merza Z; Rostami-Hodjegan A; Memmott A; Doane A; Ibbotson V; Newell-Price J; Tucker GT; Ross RJ
    Clin Endocrinol (Oxf); 2006 Jul; 65(1):45-50. PubMed ID: 16817818
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of a pre-exercise hydrocortisone dose on short-term physical performance in female patients with primary adrenal failure.
    Simunkova K; Jovanovic N; Rostrup E; Methlie P; Øksnes M; Nilsen RM; Hennø H; Tilseth M; Godang K; Kovac A; Løvås K; Husebye ES
    Eur J Endocrinol; 2016 Jan; 174(1):97-105. PubMed ID: 26494876
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Altered chemokine Th1/Th2 balance in Addison's disease: relationship with hydrocortisone dosing and quality of life.
    Ekman B; Alstrand N; Bachrach-Lindström M; Jenmalm MC; Wahlberg J
    Horm Metab Res; 2014 Jan; 46(1):48-53. PubMed ID: 23918683
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term use of continuous subcutaneous hydrocortisone infusion therapy in patients with congenital adrenal hyperplasia.
    Mallappa A; Nella AA; Sinaii N; Rao H; Gounden V; Perritt AF; Kumar P; Ling A; Liu CY; Soldin SJ; Merke DP
    Clin Endocrinol (Oxf); 2018 Oct; 89(4):399-407. PubMed ID: 30003563
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 24-Hour Profiles of 11-Oxygenated C
    Turcu AF; Mallappa A; Nella AA; Chen X; Zhao L; Nanba AT; Byrd JB; Auchus RJ; Merke DP
    Front Endocrinol (Lausanne); 2021; 12():751191. PubMed ID: 34867794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glucocorticoid replacement is permissive for rapid eye movement sleep and sleep consolidation in patients with adrenal insufficiency.
    García-Borreguero D; Wehr TA; Larrosa O; Granizo JJ; Hardwick D; Chrousos GP; Friedman TC
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4201-6. PubMed ID: 11095454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.